Ocular oncology play Aura raises $40M D round

Medicxi led a $40 million series D round for Aura as the ocular oncology company prepares its lead choroidal melanoma therapy for Phase III testing in 1H20.

The funding will give Aura Biosciences Inc. (Cambridge, Mass.) runway into 2H20, an Aura spokesperson told BioCentury, allowing it to complete Phase I/II testing for AU-011 for primary choroidal melanoma and get the company ready for two planned Phase III trials next year. AU-011 is a laser-activated viral-like particle bioconjugate therapy...